BioNTech and Pfizer’s COVID-19 vaccine will be priced beneath the usual market rates

Ryan Richardson, BioNTech’s chief strategy officer, stated that at a Financial Times virtual event that the company’s COVID-19 vaccine, partnered with Pfizer, will be priced beneath the usual market rates. Also, he expects that the vaccine will have different pricing depending on which region it is being sold to.

Richardson stated: “We’ve tried to pursue a balanced approach that recognises that innovation requires capital and investment – so we plan to price our vaccine well below typical market rates reflecting the situation that we’re in and with the goal to ensure broad-based access around the world.”